Diabetes drug found no better than placebo at treating nonalcoholic fatty liver disease
A randomised, double-blind, controlled trial of sitagliptin showed that the diabetes medication works no better than a pacebo in treating nonalcoholic fatty liver disease.
Science Daily
Source: Society for Endocrinology - Category: Endocrinology Source Type: news
More News: Diabetes | Endocrinology | Fatty Liver Disease (FLD) | Januvia | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Science | Urology & Nephrology